1. Search Result
Search Result
Results for "

RSV

" in MCE Product Catalog:

56

Inhibitors & Agonists

2

Inhibitory Antibodies

4

Natural
Products

8

Recombinant Proteins

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-130627
    RSV/IAV-IN-2

    RSV Influenza Virus Infection
    RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical drug, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections.
  • HY-130626
    RSV/IAV-IN-1

    RSV Influenza Virus Infection
    RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical drug, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections.
  • HY-143495
    RSV-IN-3

    RSV Influenza Virus Infection
    RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM).
  • HY-143496
    RSV-IN-4

    RSV Influenza Virus Infection
    RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM).
  • HY-12993
    RSV604

    A-60444

    RSV Infection
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM).
  • HY-146108
    RSV-IN-5

    RSV Infection
    RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. RSV-IN-5 exhibits potent anti-RSV activities against not only wild-type A2 F protein (EC50=2.0 nM), but also D486N-mutant F protein (EC50=8.1 nM).
  • HY-143494
    RSV/IAV-IN-3

    RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage.
  • HY-150547
    RSV-IN-6

    RSV Infection
    RSV-IN-6 (Compound 53) is an anti-RSV agent targeting M2-1 protein with EC50 values of 4.4 μM and 1.3 μM against RSV-A and RSV-B strain, respectively.
  • HY-147346
    RSV-IN-7

    RSV Infection
    RSV-IN-7 (example 253) is a RSV inhibitor (EC50: < 0.4 μΜ).
  • HY-12993B
    RSV604 (R enantiomer)

    A-60444 (R enantiomer)

    RSV Infection
    RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV.
  • HY-12993A
    RSV604 racemate

    A-60444 racemate

    RSV Others
    RSV604 (A-60444) racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.
  • HY-112673
    RSV-IN-1

    RSV Infection
    RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor, with an IC50 of 0.11 μM.
  • HY-142645
    RSV-IN-2

    RSV Infection
    RSV-IN-2 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins (wild-type, EC50 = 0.27 nM; D486N-mutant, EC50 = 0.70 nM).
  • HY-122587
    AVG-233

    DNA/RNA Synthesis RSV Infection
    AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV).
  • HY-109004A
    (S)-Enzaplatovir

    (S)-BTA-C585

    RSV Cancer
    (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77).
  • HY-109142
    Ziresovir

    AK0529; RO-0529

    RSV Infection
    Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species.
  • HY-11098
    JNJ 2408068

    R170591

    RSV Infection
    JNJ 2408068 is a potent RSV (respiratory syncytial virus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg.
  • HY-W013605A
    4-Methoxycinnamaldehyde

    p-Methoxycinnamaldehyde

    RSV Infection
    4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratory syncytial virus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL.
  • HY-104032
    Ac-CoA Synthase Inhibitor1

    RSV Infection Metabolic Disease
    Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 µM. Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV).
  • HY-P9944
    Palivizumab

    MEDI 493

    RSV Infection
    Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
  • HY-145119AS
    VV116

    JT001; GS-621763-d1 hydrobromide

    SARS-CoV RSV Influenza Virus Infection
    VV116 (JT001) is an orally active nucleoside antiviral agent against SARS-CoV-2 and respiratory syncytial virus (RSV) infection. VV116 has favorable oral bioavailability, excellent in vitro antiviral activity and selectivity.
  • HY-126033
    Sophoranol

    HBV RSV Infection
    Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL.
  • HY-126303
    GS-443902

    GS-441524 triphosphate; Remdesivir metabolite

    DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite Infection
    GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir.
  • HY-123475A
    Sisunatovir hydrochloride

    RV521 hydrochloride

    RSV Infection
    Sisunatovir (RV521) hydrochloride, an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
  • HY-123475
    Sisunatovir

    RV521

    RSV Infection
    Sisunatovir (RV521), an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
  • HY-126303C
    GS-443902 trisodium

    GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium

    DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite Infection
    GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).
  • HY-146246
    EIDD-2749

    4'-FlU; 4'-Fluorouridine

    RSV SARS-CoV HCV Infection
    EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
  • HY-119375
    Syncytial Virus Inhibitor-1

    Bacterial Infection
    Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively.
  • HY-142009
    Antiviral agent 10

    RSV Infection
    Antiviral agent 10 is an anti-viral agent that can inhibit respiratory syncytial virus (RSV).
  • HY-102038
    PC786

    RSV Infection
    PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM).
  • HY-12983
    ALS-8112

    RSV Infection
    ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
  • HY-12983A
    Lumicitabine

    ALS-008176; ALS-8176

    RSV Infection
    Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
  • HY-120632
    BMS-433771

    RSV Infection
    BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease.
  • HY-100285
    RD3-0028

    RSV Infection
    RD3-0028 is a potent and selective inhibitor of RSV replication with an EC50 of 4.5 μM.
  • HY-11097
    TMC353121

    RSV Infection
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
  • HY-12283
    Rostafuroxin

    PST 2238

    Na+/K+ ATPase RSV Cardiovascular Disease
    Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na +,K +-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity.
  • HY-112180
    Rilematovir

    JNJ-678; JNJ-53718678

    RSV Infection
    Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
  • HY-109004
    Enzaplatovir

    BTA-C585

    RSV Infection
    Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus (RSV) infection.
  • HY-16727
    Presatovir

    GS-5806

    RSV Infection
    Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC50 value of 0.43 nM.
  • HY-N1408
    trans-Trimethoxyresveratrol

    trans-trismethoxy Resveratrol; E-Resveratrol Trimethyl Ether; Tri-O-methylresveratrol

    Reactive Oxygen Species Inflammation/Immunology Cancer
    Trans-Trimethoxyresveratrol is a derivative of Resveratrol (RSV),and it may be a more potent anti-inflammatory, antiangiogenic and vascular-disrupting agent when compared with resveratrol.
  • HY-B0434
    Ribavirin

    ICN-1229

    HCV RSV Orthopoxvirus Antibiotic Infection Cancer
    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.
  • HY-P99209
    Motavizumab

    MEDI-524; Numax

    RSV Infection
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
  • HY-124512
    Quercetin pentaacetate

    Pentaacetylquercetin

    RSV Infection Inflammation/Immunology
    Quercetin pentaacetate could interact with F-protein with lower binding energy and better stability to block viral adhesion. Quercetin pentaacetate interacts with RSV and inhibit the viral adhesion on cell surface.
  • HY-B0434S
    Ribavirin-13C5

    ICN-1229-13C5

    HCV RSV Antibiotic Infection
    Ribavirin-13C5 (ICN-1229-13C5) is the 13C-labeled Ribavirin. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.
  • HY-N3811
    ent-11β-Hydroxyatis-16-ene-3,14-dione

    RSV Infection
    ent-11β-Hydroxyatis-16-ene-3,14-dione (compound 11) is a diterpenoid from the fresh roots of Euphorbia jolkinii. ent-11β-Hydroxyatis-16-ene-3,14-dione has anti-RSV activity.
  • HY-N6025
    Clemastanin B

    Influenza Virus Infection Inflammation/Immunology
    Clemastanin B, a lignin, has potent anti-influenza activities by inhibiting the virus multiplication, prophylaxsis and blocking the virus attachment. Clemastanin B targets viral endocytosis, uncoating or ribonucleoprotein (RNP) export from the nucleus. Clemastanin B has antioxidant and anti-inflammatory activities.
  • HY-151269A
    SARS-CoV-2-IN-23 disodium

    SARS-CoV Infection
    SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM.
  • HY-151269
    SARS-CoV-2-IN-26

    SARS-CoV Infection
    SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
  • HY-151276A
    SARS-CoV-2-IN-29 disodium

    SARS-CoV Infection
    SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC50 value of 3.0 μM.
  • HY-151278
    SARS-CoV-2-IN-30

    SARS-CoV Infection
    SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC50 value of 6.9 μM.
  • HY-151276
    SARS-CoV-2-IN-29

    SARS-CoV Infection
    SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC50 value of 3.0 μM.
  • HY-151278A
    SARS-CoV-2-IN-30 disodium

    SARS-CoV Infection
    SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC50 value of 6.9 μM.
  • HY-151274
    SARS-CoV-2-IN-28

    SARS-CoV Infection
    SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
  • HY-151274A
    SARS-CoV-2-IN-28 disodium

    SARS-CoV Infection
    SARS-CoV-2-IN-28 disodium is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 disodium exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM.
  • HY-151271
    SARS-CoV-2-IN-27

    SARS-CoV Infection
    SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC50 value of 6.5 μM.
  • HY-151271A
    SARS-CoV-2-IN-27 disodium

    SARS-CoV Infection
    SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC50 value of 6.5 μM.